-
Anticholinergic drugs for COPD; pioglitazone for diabetes prevention; insulin degludec in Phase 3 trials; and FDA Actions.
-
Patients with localized but non-resectable lung cancer generally are considered candidates for other types of therapy including external beam or stereotactic radiation therapy, chemotherapy, or percutaneous ablation.
-
A 58-year-old auto salesman was referred for initial management of metastatic pancreatic cancer. He had been well until approximately 3 months prior when he began to experience epigastric and mid-back pain.
-
Approximately 10% of patients with newly diagnosed acute myelogenous (AML) leukemia have a history of prior treatment with chemotherapy, radiation, or both (t-AML).
-
-
Using the SEER database, data for patients with adenocarcinoma of the pancreas diagnosed in 1995-2005 were analyzed for the occurrence of suicide. As expected, the rates were higher than those reported for the general population, but among men, particularly those who were recovering from surgery, the mortality rate from suicide was 10 times greater than that of the general population. Care providers should be aware of this heightened risk and intervene as possible.
-
Among three distinct cohorts of lung cancer patients and matched controls (without tumor), the authors present data on the capacity for an assay that detects antibody to tumor-associated antigens to discriminate those with lung cancer and those without. Using a panel of six antigens, they found their assay to have sensitivity/specificity of approximately 40%/90%. If confirmed in an independent prospective study, such screening may be a very effective adjunct to imaging studies in the early recognition of lung cancer.
-
The optimal standard salvage therapy for relapsed or refractory AML remains undetermined. The authors retrospectively compared two regimens at a single institution: CLAG (cladribine, high-dose cytarabine, and G-CSF) with MEC (mitoxantrone, etoposide, and cytarabine). These observational data without adjustment suggest CLAG may be superior to MEC. Nevertheless, outcomes for relapsed or refractory AML remain poor and clinical trials should be entertained when available.
-
Apixaban and rivaroxaban near approval for nonvalvular atrial fibrillation; fidaxomicin for C. difficile infections; guideline for intensive insulin therapy; and FDA Actions.
-
